Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214173 · ClinicalTrials.gov registry record · NA
The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV
A NA study of Human Immunodeficiency Virus Infection, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT02214173: Completed NA study of Human Immunodeficiency Virus Infection, sponsored by University of Miami.
NCT02214173 is a NA study of Human Immunodeficiency Virus Infection that has completed, run by University of Miami. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02214173, a NA study of Human Immunodeficiency Virus Infection, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effects of the nutritional supplement rice bran arabinoxylan compound (RBAC) on metabolic syndrome variables in persons living with HIV. The hypothesis is that there will be a significant improvement in metabolic syndrome and immune variables in HIV-positive participants in the intervention group compared to the control group.
Primary Outcome
Improvement in glucose, lipid profile, blood pressure, cluster of differentiation 4 (CD4), and cluster of differentiation 8 (CD8) values.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT rice bran arabinoxylan compound (RBAC)
Study Locations (1)
Florida
- University of Miami Miller School of Medicine, Clinical Research Building, Department of Psychiatry & Behavioral Sciences - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-06 |
| Phase | NA |
What the finished NCT02214173 record still lists
NCT02214173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Human Immunodeficiency Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02214173 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02214173 about?
NCT02214173 is a clinical study titled "The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV". The purpose of this study is to investigate the effects of the nutritional supplement rice bran arabinoxylan compound (RBAC) on metabolic syndrome variables in persons living with HIV. The hypothesis is that there will be a significant improvement in metabolic syndrome and immune variables in HIV-po...
What is the current status of trial NCT02214173?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2015-01. Estimated completion is 2016-06.
What conditions does trial NCT02214173 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus Infection.
What interventions are being tested in trial NCT02214173?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), rice bran arabinoxylan compound (RBAC) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02214173?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02214173 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02214173's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia